Targeted delivery of antineoplastic agent to bone: Biodistribution studies of technetium-99m-labeled gem-bisphosphonate conjugate of methotrexate

Journal of Nuclear Medicine

Volumn 37, Issue 1, 1996, Pages 105-107

  Hosain, Fazle ^a   Spencer, Richard P ^b   Couthon, Helene M ^b   Sturtz, Georges L ^b  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b NONE

Author keywords

bisphosphonate; bone tumors; methotrexate; technetium 99m diphosphonate

Indexed keywords

METHOTREXATE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE TUMOR; DRUG DISTRIBUTION; HUMAN; IMAGE ANALYSIS; IMAGE DISPLAY; OSTEOSARCOMA; PRIORITY JOURNAL; QUALITY CONTROL; RADIOACTIVITY;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BONE AND BONES; BONE NEOPLASMS; DIPHOSPHONATES; MALE; METHOTREXATE; MICE; OSTEOSARCOMA; RABBITS; SODIUM PERTECHNETATE TC 99M; TISSUE DISTRIBUTION;

EID: 0029916520     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Robinson RG, Preston DF, Spicer JA, Baxter KG. Radionuclide therapy of intractable bone pain: emphasis on strontium-89. Semin Nucl Med 1992;22:28-32.
2. Jung A, Bisaz S, Fleisch H. The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals. Culcif Tissue Res 1973,11.269-280.
3. Fogelman I, Maisey MM, Clarke SEM, An atlas of clinical nuclear medicine. St. Louis' Mosby, 1994:1-110.
4. Sturtz G, Appere G, Breistol K, Fodstad O, Schwartsmann G, Hendriks HH. A study of the delivery-targeting concept applied to antineoplastic drugs active on human osteosarcoma. I Synthesis and biological activity in nude mice carrying human osteosarcoma xenografts of gem-bisphonic methotrexate analogues. Eur J Med Chem 1992;27:825-833
5. Jaffe N Recent advance in the chemotherapy of metastatic osteogenic sarcoma. Cancer 1972;30.1627-1630
6. Sturtz G, Couthon H, Fabulet O, Mian M, Rosmi S. Synthesis of gem-isphosphonic methotrexate conjugates and their biological response towards Walker's osteosarcoma. Eur J Med Chem 1993;28.899-903.
7. Wang TST, Hosam P, Spencer RP, Ahlquist K., Hosain F. Synthesis, radiotechnetium labeling and comparison of biologic behavior of longer-chain analogs of methylene diphosphonatc. J Nucl Med 1978,19:1151-1153
8. Surh Y, Spencer RP, Spitznagle LA, Hosam F, Lejczak B. Technetium-99m-labeled phosphonic acid analog of serine, bone uptake. J Nucl Med 1986;27.847-849.
9. Robbins PJ. Chromatography of technetnum-99m radiopharmaceuticals - a practical guide, New York: Society of Nuclear Medicine: 1985:11-20.
10. Wingen F, Sterz H, Blum H, et al Synthesis, antitumor activity, distribution and toxicity of 4-[4-[bis(2-chloroethyl)atnino]phenyl]-1-hydroxybutane-11-bisphosphonic acid (BAD), a new lost derivative with increased accumulation in rat osteosarcoma. J Cancel Res Clin Oncol 1986, 111:209-219
11. Maxon HR III, Schroder LE, Thomas SR, et al. Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: imitial clinical experience in 20 patients with hormone-resistant prostate cancer Radiology 1990;176.155-159.
12. Johns DG, Spencer RP, Chang PK, Bertino JR Iodine-131-3′-iodoaminopterin a gamma-labeled active-site-directed enzyme inhibitor. J Nucl Med 1969;10:530-536.